bkt-140
Peptideexperimental
Clinical trial activity
11 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT01010880)
Timeline
Indications
Studied for
- Anemia, Aplastic · Phase 2
- Hodgkin Disease · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Pancreatic Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Stem Cells · Phase 1
Mechanism of action
- C-X-C chemokine receptor type 4ANTAGONIST
CXCR4 antagonist
- C-X-C chemokine receptor type 4INHIBITOR
CXCR4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545348 ↗
Also known as
- bkt140
- bkt140
- bkt140
- bkt-140
- bkt-140
- bl-8040
- bl-8040
- bl-8040
- t140
- t140
- t140
- t140 peptide
- tf-14016
- tf-14016
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03154827 | Phase 1/Phase 2 (Phase 2) | Sep 17, 2017 | BioLineRx, Ltd., Genentech |
| NCT02763384 | Phase 2 | Dec 2, 2016 | Washington University in St. Louis |
| NCT02907099 | Phase 2 | Dec 1, 2016 | BioLineRx, Ltd., Merck, University of Texas at Houston |
| NCT02826486 | Phase 2 | Sep 1, 2016 | BioLineRx, Ltd., Merck |
| NCT02639559 | Phase 2 | Mar 31, 2016 | BioLineRx, Ltd., Washington University in St. Louis |
| NCT02462252 | Phase 2 | Oct 1, 2015 | BioLineRx, Ltd., University of Texas at Houston |
| NCT02502968 | Phase 2 | Sep 1, 2015 | BioLineRx, Ltd., Martin Luther University, University of Halle |
| NCT02115672 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2014 | Tel Aviv University |
| NCT02073019 | Phase 1 | Aug 1, 2014 | BioLineRx, Ltd. |
| NCT01838395 | Phase 2 | Apr 1, 2013 | BioLineRx, Ltd. |
| NCT01010880 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2008 | Biokine Therapeutics Ltd, Tel Aviv University |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioLineRx, Ltd. | For profit | 8 | 5 | 2 | 2013 |
| Merck | For profit | 2 | 0 | 1 | 2016 |
| Tel Aviv University | Academic/Hospital | 2 | 1 | 1 | 2008 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 1 | 2015 |
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Biokine Therapeutics Ltd | For profit | 1 | 1 | 1 | 2008 |
| Genentech | For profit | 1 | 0 | 1 | 2017 |
| Martin Luther University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Halle | Academic/Hospital | 1 | 0 | 1 | 2015 |
9 organizations
Page 1 / 1